Overexpression of cyclooxygenase-2 in multiple myeloma: Association with reduced survival

American Journal of Hematology

Volumn 80, Issue 3, 2005, Pages 169-173

  Cetin, Mustafa ^a   Buyukberber, Suleyman ^b   Demir, Muzaffer ^c   Sari, Ismail ^a,e   Sari, Ibrahim ^d   Deniz, Kemal ^d   Eser, Bulent ^a   Altuntas, Fevzi ^a   Camci, Celalettin ^a   Öztürk, Ahmet ^b   Turgut, Burhan ^c   Vural, Özden ^c   Unal, Ali ^a  

^a ERCIYES UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c TRAKYA UNIVERSITY   (Turkey)

^d GAZIANTEP UNIVERSITY   (Turkey)

^e ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Angiogenesis; COX 2 expression; Estimated survival; Multiple myeloma

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; LACTATE DEHYDROGENASE;

ADULT; AGED; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW BIOPSY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; ANALYSIS OF VARIANCE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 27644525342     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20460     Document Type: Article

References (28)

1. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18: 7908-7916.
2. Moehler TM, Hillengass J, Goldschmidt H, Ho AD. Antiangiogenic therapy in hematologic malignancies. Curr Pharm Des 2004;10: 1221-1234.
3. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
4. Masferrer JL, Koki A, Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann NY Acad Sci 1999;889:84-86.
5. Thun MJ, Henley SJ, Patrono J. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-266.
6. Giles FJ, Kantarjian HM, Bekele BN, et al. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br J Haematol 2002;119:38-45.
7. Soslow RA, Dannenberg AJ, Rush D, et al. Cox-2 is expressed in human pulmonary, colonic and mammary tumours. Cancer 2000; 89:2637-2645.
8. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
9. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
10. Weidner N, Semple JP, Welch, WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
11. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol 1996;167-190.
12. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000;96:3374-3380.
13. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-2245.
14. Schneider P, Jerome MV, Paysant J, Soria PC, Vannier JP. The role of angiogenesis in leukemia proliferation. Am J Pathol 1999; 155:1007-1008.
15. Zetterberg E, Lundberg LG, Palmblad J. Expression of cox-2, tie-2 and glycodelin by megakaryocytes in patients with chronic myeloid leukaemia and polycythaemia vera. Br J Haematol 2003; 121:497-499.
16. Vacca A, Ribatti D, Roncali L, Dammacco F. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk Lymphoma 1995;20:27-38.
17. Baur A, Bartl R, Pellengahr C, Baltin V, Reiser M. Neovascularization of bone marrow in patients with diffuse multiple myeloma. Cancer 2004;101:2599-2604.
18. Sezer O, Niemoller K, Eucker J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 2000;79:574-577.
19. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6:3111-3116.
20. Vacca A, Ribatti D, Roncali L, Dammacco F. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-508.
21. Chiarugi V, Magnelli L, Gallo O. Cox-2, iNOS and p53 as playmakers of tumor angiogenesis. Int J Mol Med 1998;2:715-719.
22. Liu XH, Kirschenbaum A, Yao S, et al. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis 1999; 17:687-694.
23. Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M. Cyclooxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000;130:641-649.
24. Kumar S, Witzig TE, Timm M, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004;104:1159-1165.
25. Yuan A, Pan-Chyr Y, Kwen-Tay L. Tumoral cyclooxygenase-2 (COX-2) overexpression correlates with vascular endothelial growth factor (VEGF) expression and angiogenesis, and associated with short survival and early relapse in non-small cell lung cancer. Proc Am Assoc Cancer Res 2003;44:928 (abstract 4057).
26. Sezer O, Jakob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic fibroblastic growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001;66:83-88.
27. Rosinol L, Cibeira MT, Segarra M, et al. Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine 2004;26:145-148.
28. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclooxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001;2:544-551.